Research programme: melanocortin-4 receptor agonists - Novo Nordisk

Drug Profile

Research programme: melanocortin-4 receptor agonists - Novo Nordisk

Alternative Names: Melanocortin-4 receptor agonists research programme - Novo Nordisk; NNC 70-619; Obesity therapy research programme - Novo Nordisk

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Piperazines; Small molecules
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in Denmark
  • 08 Dec 2004 Data presented at the Annual Scientific Meeting of the North American Association for the Study of Obesity (NAASO-2004) have been added to the adverse events and Obesity pharmacodynamics sections
  • 07 Sep 2004 Preclinical trials in Obesity in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top